Cosmo Pharmaceuticals N.V (C43) - Total Liabilities

Latest as of December 2025: €123.46 Million EUR ≈ $144.34 Million USD

Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) has total liabilities worth €123.46 Million EUR (≈ $144.34 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Cosmo Pharmaceuticals N.V equity growth rate to track the company's year-over-year net asset growth rate.

Cosmo Pharmaceuticals N.V - Total Liabilities Trend (2016–2025)

This chart illustrates how Cosmo Pharmaceuticals N.V's total liabilities have evolved over time, based on quarterly financial data. See Cosmo Pharmaceuticals N.V free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Cosmo Pharmaceuticals N.V Competitors by Total Liabilities

The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their total liabilities.

Company	Country	Total Liabilities
Polestar Automotive Holding UK PLC Class A ADS NASDAQ:PSNY	USA	$7.91 Billion
Peptron Inc KQ:087010	Korea	₩37.42 Billion
Tong Yang Industry Co Ltd TW:1319	Taiwan	NT$8.58 Billion
Hengdian Group Tospo Lighting Co Ltd SHG:603303	China	CN¥2.51 Billion
Zhejiang Jingu Co Ltd SHE:002488	China	CN¥5.18 Billion
Avanti Feeds Limited NSE:AVANTIFEED	India	Rs8.31 Billion
Jiangsu Cai Qin Technology Co Ltd SHG:688182	China	CN¥401.94 Million
North Long Dragon New Materials Technology Co. Ltd. A SHE:301357	China	CN¥89.67 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Cosmo Pharmaceuticals N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see C43 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.18	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cosmo Pharmaceuticals N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cosmo Pharmaceuticals N.V (2016–2025)

The table below shows the annual total liabilities of Cosmo Pharmaceuticals N.V from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€123.46 Million ≈ $144.34 Million	-12.86%
2024-12-31	€141.68 Million ≈ $165.64 Million	+15.73%
2023-12-31	€122.42 Million ≈ $143.12 Million	-58.61%
2022-12-31	€295.80 Million ≈ $345.83 Million	+1.00%
2021-12-31	€292.88 Million ≈ $342.41 Million	+49.40%
2020-12-31	€196.04 Million ≈ $229.19 Million	+2.41%
2019-12-31	€191.43 Million ≈ $223.80 Million	+5.86%
2018-12-31	€180.83 Million ≈ $211.41 Million	+549.14%
2017-12-31	€27.86 Million ≈ $32.57 Million	-0.21%
2016-12-31	€27.92 Million ≈ $32.64 Million	--

About Cosmo Pharmaceuticals N.V

F:C43 Germany Drug Manufacturers - General

Market Cap

$1.33 Billion

€1.13 Billion EUR

Market Cap Rank

#7597 Global

#1046 in Germany

Share Price

€66.20

Change (1 day)

+1.69%

52-Week Range

€57.50 - €139.00

All Time High

€153.25